Evidence map›Paper›PMID 35211306›Full record

ArticleClinical kidney journal2022

Urine metabolic risk factors and outcomes of patients with kidney transplant nephrolithiasis.

Erin Bolen, Karen Stern, Mitchell Humphreys, Alexandra Brady, Todd Leavitt, Nan Zhang, Mira Keddis

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Factors associated withFrontiers in medicine · 2026
    Article
  3. Article
  4. Review
  5. Management ofClinical kidney journal · 2024
    Review
  6. Clot stones in transplant kidneys.BMJ case reports · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Erin BolenMayo Clinic Alix School of Medicine, Scottsdale, AZ, USA.
Karen SternDepartment of Urology, Mayo Clinic, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, USA.
Mitchell HumphreysDepartment of Urology, Mayo Clinic, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, USA.
Alexandra BradyDepartment of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ, USA.
Todd LeavittDepartment of Statistics, Mayo Clinic, Scottsdale, AZ, USA.
Nan ZhangDepartment of Statistics, Mayo Clinic, Scottsdale, AZ, USA.
Mira KeddisDepartment of Nephrology and Hypertension, Mayo Clinic, Scottsdale, AZ, USA.ORCID https://orcid.org/0000-0001-8249-0848
Mayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNephrolithiasis in allograft kidneys is rare, but this diagnosis may lead to allograft complications and patient morbidity. Previous studies that have evaluated nephrolithiasis posttransplant have focused on surgical stone management, with limited data on urine metabolic risk factors and the presence of stones after follow-up.

methodsWe retrospectively evaluated kidney transplant recipients who were diagnosed with transplant nephrolithiasis between 2009 and 2019. Computed tomography and ultrasound imaging were used to confirm stone presence.

resultsThe incidence of allograft kidney stone formation was 0.86% of 6548 kidney transplant recipients. Of the 56 cases identified, 17 (30%) had a pretransplant history of nephrolithiasis. Only four (7%) patients received a known kidney stone at the time of allograft implantation. Of the 56 cases, 34 had a 24-h supersaturation study. The urine supersaturation study showed 32 patients (94%) had a urine citrate of <450 mg excreted in 24 h (median 124.5 mg/24 h, reference range >500 mg/24 h), along with 22 patients (61%) having a urine oxalate excretion of ≥30 mg in 24 h (median 34.4 mg/24 h, reference range <30 mg/24 h). Calcium oxalate composition was most common (91% with >1 supersaturation for calcium oxalate crystals), with normal median urine calcium levels (median urine calcium 103.5 mg/24 h, reference range <200 mg/24 h). After a 4-year follow-up, 50% (

conclusionsThis is the largest study of transplant nephrolithiasis confirming that hypocitraturia and hyperoxaluria were the most significant urine metabolic risk factors associated with allograft nephrolithiasis and that hyperoxaluria was the most prevalent driver for calcium oxalate stone composition. Our study is first to show low stone-free rates at the last follow-up and a significant proportion requiring surgical intervention.

Indexed as

hyperoxaluriahypocitraturiakidney stonekidney transplantationnephrolithiasis

Identifiers

PMID35211306
PMCPMC8862062
OpenAlexW3209925709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.